Архив в PDF формате
Дата публикации статьи в журнале: 2020/03/16
Название журнала: Восточно Европейский Научный Журнал, Выпуск: 54, Том: 3, Страницы в выпуске: 52-58
Анотация: Diabetic retinopathy (DR) is diagnosed in 50% of patients with type 1 diabetes (DM) with a disease duration of 10-15 years and in 75-90% of patients with a diabetes duration of more than 15 years . Vascular pathology correction is one of the important DR treatment directions. The number of patients with DM increases annually and according to the State Register of the Ministry of Healthcare of Ukraine in Ukraine is already more than 1 million people, which is slightly less than 2% of the total population [2-4]. In this case, diabetic retinopathy has a special place among the complications of type 2 diabetes [5, 6]. DR, as one of the most frequent and adverse manifestations of diabetes, remains the leading cause of significant visual impairment [2, 7 - 10]. Retina microstructural changes are detected at the DM onset, they gradually trigger the pathogenetic reactions cascade [11-14], which lead to microcirculation infringement and tissue hypoxia. Endothelial dysfunction is one of the key links in vascular dysfunction in diabetes . There are a number of clinical and experimental studies in the literature that associated with endothelial disorders and arteries elastic properties to the diabetes vascular complications development [16-19]. Endothelial dysfunction (ED) leads to impaired nitric oxide (NO) synthesis, which plays an important physiological role, having a wide range of bioregulatory effects [20 - 22]. NO is characterized by vascular tone regulation, proliferation and apoptosis, oxidative processes regulation, angioprotective properties. All this is necessary for the vascular homeostasis regulation. It is also a strong peripheral vasodilator . The main substrate for NO synthesis is arginine . It performs number of important functions in the body, but its main role is that it's substrate for the nitric oxide synthesis [23-26]. Therefore, for the correction of ED, in particular for DM, this amino acid from which the endothelium can synthesize the necessary substances .
Данные для цитирования: Semenko V.V. , . ENDOTHELINE-1’s DYNAMICS IN NON-PROLIFERATIVE DIABETIC RETINOPATHY AND ITS CORRECTION WITH LARGININE (52-58). Восточно Европейский Научный Журнал. Медицинские науки. 2020/03/16; 54(3):52-58.